Benzo five-membered heterocyclic sulfonamide compound, its preparation method, pharmaceutical composition and application

A compound and pharmaceutical technology, applied in drug combination, organic chemistry, digestive system, etc., can solve the problems of high toxicity and side effects of PPAR agonists, single structure of PPARα/γ/δ broad-spectrum agonists, etc., and achieve good therapeutic effect, good Stimulant activity, less toxic and side effects

Active Publication Date: 2022-04-08
瀚海新拓(杭州)生物医药有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The technical problem to be solved in the present invention is to overcome the defects of relatively large toxic and side effects of existing PPAR agonists and the single structure of PPARα / γ / δ broad-spectrum agonists, and provide a benzo five-membered heterocyclic sulfonamide compound, its Preparation method, pharmaceutical composition and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Benzo five-membered heterocyclic sulfonamide compound, its preparation method, pharmaceutical composition and application
  • Benzo five-membered heterocyclic sulfonamide compound, its preparation method, pharmaceutical composition and application
  • Benzo five-membered heterocyclic sulfonamide compound, its preparation method, pharmaceutical composition and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0232] Embodiment 1: the synthesis of compound S1

[0233]

[0234] Step 1: Synthesis of compound 3a

[0235] Compound 1a (5 g, 46.3 mmol), compound 2a (5.3 g, 46.3 mmol) and TEA (13 mL, 92.6 mmol) were dissolved in 1,4-dioxane and stirred at room temperature for 3 h. After the reaction of the raw materials is complete, the precipitated solid is suction-filtered, and the filter cake is washed three times with 1,4-dioxane. Dissolve the filter cake in 25mL of acetic acid, add 10mL of concentrated hydrochloric acid, and heat to reflux for 2h. The volatile substances were distilled off under reduced pressure, and then the resulting solid was suspended in 45 mL of acetone while it was hot, stirred, cooled to room temperature, filtered with suction, washed with acetone three times, and the filter cake was vacuum-dried to obtain compound 3a (5.6 g, 60%). 1 H NMR (500MHz, DMSO-d 6 )δ12.03(s,1H),7.54–7.48(m,1H),7.46–7.40(m,1H),7.19–7.08(m,2H),2.69(t,J=6.4Hz,2H),2.43 (t,J=7.0Hz,2...

Embodiment 2

[0239] Embodiment 2: the synthesis of compound S2

[0240]

[0241] 1 H NMR (500MHz, DMSO-d 6 )δ12.11(s,1H),8.36(s,1H),7.98(dd,J=8.3,2.3Hz,1H),7.95–7.86(m,2H),7.78(d,J=8.5Hz,1H ), 7.36(d, J=2.3Hz, 1H), 7.31–7.25(m, 1H), 2.99(t, J=6.4Hz, 2H), 2.82(s, 3H), 2.45(t, J=7.3Hz ,2H 2H),2.20–2.11(m,2H). 13 C NMR (125MHz, DMSO-d 6 )δ 177.32, 156.48, 152.08, 151.20, 144.62, 142.82, 135.98, 135.31, 134.81, 125.33, 122.94, 121.32, 120.60, 113.75, 110.75, 33.49, 30.51, 22.959, 2

Embodiment 3

[0242] Embodiment 3: the synthesis of compound S3

[0243]

[0244] 1 H NMR (500MHz, DMSO-d 6 )δ12.11(s,1H),8.35(s,1H),7.96–7.83(m,4H),7.36(dd,J=8.1,1.8Hz,1H),7.12(td,J=8.2,1.8Hz ,1H),3.06(t,J=6.4Hz,2H),2.40(t,J=7.1Hz,2H),2.23–2.14(m,2H). 13 C NMR (125MHz, DMSO-d 6 )δ177.30,161.24,159.22,157.02,152.08,151.18,144.60,142.92,142.86,135.20,135.17,134.83,122.94,121.32,114.94,114.88,113.65,113.49,110.72,105.67,105.51,33.48,30.49,22.99.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a benzo five-membered heterocyclic sulfonamide compound, its preparation method, pharmaceutical composition and application. The invention specifically discloses a compound represented by formula I, its pharmaceutically acceptable salt, its isomer, its metabolite or its prodrug. The phenyl five-membered heterocyclic sulfonamides of the present invention have good agonistic activity on PPARα / γ / δ, and have good therapeutic effect on non-alcoholic fatty liver (NASH). The invention also discloses the preparation method and application of the compound represented by formula I.

Description

technical field [0001] The invention belongs to the field of innovative drugs, and relates to a benzo five-membered heterocyclic sulfonamide compound, a preparation method, a pharmaceutical composition and an application thereof. Background technique [0002] Metabolic syndrome (MS for short) refers to the pathological state of metabolic disorders of protein, fat, carbohydrates and other substances in the human body. Metabolic syndrome includes many pathological factors, insulin resistance, hyperinsulinemia, abdominal obesity, impaired glucose tolerance, type 2 diabetes mellitus, microalbuminuria, high triglyceride levels, low HDL cholesterol levels, hypertension, high uric acid, High prevalence of fatty liver, proinflammatory and prothrombotic state. Peroxisome proliferator-activated receptors (PPARs for short) are a class of ligand-dependent nuclear hormone receptors that belong to the steroid receptor superfamily and can induce and inhibit the expression of various genes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D413/12C07D417/12A61K31/423A61K31/428A61P3/00A61P3/10A61P1/16
CPCC07D413/12C07D417/12A61P3/00A61P3/10A61P1/16
Inventor 张霁蒋晟
Owner 瀚海新拓(杭州)生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap